Labcorp Holdings Inc Stock Price, News & Analysis

Labcorp (NYSE: LH) has announced a strategic partnership with MD Anderson Cancer Center Foundation Spain to enhance oncology clinical trials. This collaboration aims to accelerate cancer therapy development by prioritizing early phase trials at MD Anderson's facilities in Spain. With over 1,000 oncology studies globally, Labcorp continues to be a leader in drug development, emphasizing the importance of Phase I trials in the therapy approval process. This partnership positions MD Anderson as a reference center in Europe for innovative cancer treatments.

Labcorp (NYSE: LH) announced it will begin testing for monkeypox using the CDC's orthopoxvirus test, enhancing access to testing during the ongoing outbreak. Labcorp is the first national laboratory to offer this PCR test and aims to increase testing capacity to 10,000 tests per week, doubling the current capacity. Initially performed in North Carolina, testing can expand nationwide if necessary. The public will need to consult healthcare providers for sample collection and testing initiation. This initiative underscores Labcorp's commitment to public health.

Labcorp (NYSE: LH) has announced a strategic partnership with BML to expand its central laboratory capabilities in Japan. The new facility in Kawagoe will enhance their services for global clinical trials, increasing capacity over fivefold to 4,000 square meters. This expansion is set to be completed by early 2025, allowing Labcorp to offer improved turnaround times and services for pharmaceutical clients. The partnership, which dates back over a decade, aims to deepen collaboration in biomarker testing and precision medicine, positioning Labcorp as an oncology leader.

Labcorp (NYSE: LH) has announced a collaboration with HealthVerity to enhance its drug development and clinical trial programs through real-world data (RWD). This partnership aims to provide improved access to HIPAA-compliant data, facilitating faster patient enrollment and better trial outcomes. With HealthVerity's platform, Labcorp can achieve greater accuracy in aligning de-identified patient data. This strategic move supports Labcorp's commitment to delivering comprehensive solutions in drug and diagnostics development, crucial for the evolving landscape of clinical research.

Labcorp (NYSE: LH) has launched a new sponsored testing program for advanced non-small cell lung cancer (NSCLC) patients, enhancing access to precision medicine. This initiative aims to aid informed treatment decisions by utilizing Labcorp’s OmniSeq INSIGHT test, which provides comprehensive genomic and immune profiling. Sponsored by Eli Lilly, the program seeks to identify actionable biomarkers, potentially improving patient outcomes and expanding eligibility for clinical trials. Labcorp's commitment to precision medicine is highlighted through this collaboration, furthering advancements in cancer care.

Labcorp (NYSE: LH) has launched a new test measuring LAG-3 expression in melanoma patients, which could enhance treatment options. This assay, developed for clinical trials, provides critical data for evaluating new cancer therapies, particularly those targeting LAG-3. Labcorp aims to improve patient care by offering diagnostic solutions that guide clinical decisions. With skin cancer being the most common cancer in the U.S., this advancement represents a significant step in combating melanoma. The assay's clinical application could lead to improved patient outcomes.

Labcorp (NYSE: LH) has received Emergency Use Authorization (EUA) from the FDA for a new at-home collection kit that tests for COVID-19, influenza A/B, and RSV. This combined kit offers reliable PCR testing from the comfort of home, aimed at individuals aged 2 and older. Tests can be ordered through Labcorp OnDemand without a prescription and may incur no upfront cost for those with insurance. Labcorp has conducted over 74 million COVID-19 tests and continues to innovate in response to respiratory virus prevalence.

Labcorp (NYSE: LH), a global life sciences leader, will participate in a fireside chat at the UBS 2022 Global Healthcare Conference on May 24 at 2:45 p.m. ET. A live webcast will be available on the Labcorp Investor Relations website. With over 75,000 employees and a revenue of $16 billion in 2021, Labcorp provides critical diagnostic and drug development insights worldwide.

Labcorp has launched an at-home Diabetes Risk Test Kit through Labcorp OnDemand, offering a convenient way for individuals to assess their diabetes risk. The test utilizes a new blood collection device, Weavr Velvet, which has received approval for HbA1c testing from New York State. This easy-to-use kit allows consumers to collect a small blood sample at home, with results showing over 97% accuracy compared to traditional blood draws. This initiative aims to empower more Americans to understand and manage their health regarding diabetes.